Aspirin for Primary Prevention: 2016 USPSTF Recommendations
The 2016 USPSTF recommendations for use of aspirin for primary prevention are just out and should make life easier for primary care clinicians. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - April 14, 2016 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines
On December 16, 2015, the FDA announced it is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics. The REMS is no longer necessary to ensure that the benefits of rosiglitazone medicines outweigh their risks. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 30, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA cautions about dosing errors when switching between different oral formulations of antifungal Noxafil (posaconazole); label changes approved
On January 4, 2016 FDA cautioned that differences in dosing regimens between the two oral formulations of the antifungal Noxafil (active ingredient posaconazole) have resulted in dosing errors. To help prevent additional medication errors, the drug labels were revised to indicate that the two oral formulations cannot be directly substituted for each other but require a change in dose. Direct milligram for milligram substitution of the two formulations can result in drug levels that are lower or higher than needed to effectively treat certain fungal infections. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 30, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about several safety issues with opioid pain medicines; requires label changes
On March 22, 2016, FDA announced warnings about several safety issues with the entire class of opioid pain medicines. These safety risks are potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. We are requiring changes to the labels of all opioid drugs to warn about these risks. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 30, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
On December 4, 2015, FDA announced a safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of ketoacidosis and of serious urinary tract infections (UTIs). Both conditions can result in hospitalization. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 30, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Generic vs Brand-Name Epilepsy Drugs
Dr Ting talks with Dr Wilner about the results of her study on the bioequivalence of generic and brand-name drugs for epilepsy. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - February 29, 2016 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
Adult Immunization 2016: What's New?
Keeping up with the changes to adult immunization schedules can be onerous…unless you have this quick summary of what's new for 2016! (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - February 1, 2016 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
Dimitrios P. Kontoyiannis, MD, MS, ScD, FACP, FIDSA - Principles and Application of Antifungal Pharmacology: A Case-Based Approach to Optimizing Treatment Decisions in Individual Patients With Invasive Fungal Infections
Principles and Application of Antifungal Pharmacology: A Case-Based Approach to Optimizing Treatment Decisions in Individual Patients With Invasive Fungal Infections (Source: PeerView CME/CE Audio Podcast - Immunology)
Source: PeerView CME/CE Audio Podcast - Immunology - December 11, 2015 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
FDA Drug Safety Podcast: FDA advises of rare cases of underactive thyroid in infants given iodine-containing contrast agents for medical imaging
On November 17, 2015, FDA announced it is advising that rare cases of underactive thyroid have been reported in infants following the use of contrast media containing iodine, also called “contrast dye,” for X-rays and other medical imaging procedures. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - November 30, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
PrEP: Simple and Effective Yet Underused
Despite being an important way for clinicians to protect their patients from becoming infected with HIV, PrEP continues to be underused. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - November 30, 2015 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
The Safety of SSRIs During Pregnancy
Results from a large, prospective study of expectant Finnish mothers looked at the safety of SSRIs during pregnancy. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - November 24, 2015 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death
On November 6, 2015 FDA announced that a review has determined that long-term use of the blood-thinning drug Plavix (active ingredient clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - November 10, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA review found no increased cardiovascular risks with Parkinson’s disease drug entacapone
On October 26, 2015 FDA announced an FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson’s disease. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - November 6, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate)
On October 22, 2015, the FDA announced it is requiring the Kayexalate manufacturer to conduct studies to investigate Kayexalate’s potential to bind to other medications administered by mouth – drug interactions that could affect how well the other medications work. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - October 30, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
On October 22, 2015 FDA announced it is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - October 30, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
